Clinical Trial Update: FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3 [Phase 1]

View source ↗

Summary

FORAGER-1 is a Phase 1 study of LOXO-435 (LY3866288) in participants with FGFR3 alterations, with recruitment ongoing in cancers including bladder and ureteral …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Ureteral Cancer
• Urinary Bladder Cancer

Drugs mentioned

• LOXO-435 (LY3866288) (LOXO-435)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Urinary Bladder Neoplasms, Neoplasm Metastasis | Phase 1 | Status: RECRUITING